Stocks · News reference
Fennec Pharmaceuticals (NASDAQ:FENC) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 145.45 percent increase over losses of $(0.11) per share
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
Read original at benzingaWedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
Read original at benzinga